Publications and related articles about us and the wound care industry

Piomic Medical Wins EPUAP 2024 Most Innovative Product Award

04 Oct 2024

Award highlights promising potential of COMS® therapy for severe pressure ulcers, with off-label data showing “clinically significant rates of wound area reduction and wound closure“1.

Read more
Piomic Medical Wins EPUAP 2024 Most Innovative Product Award
New Study Reconfirms COMS® Effectiveness and Gives Insights to Potential New Applications for Wound Care

23 Aug 2024

New Study highlights COMS® as a promising tool for debridement and wound bed preparation for other therapies, such as skin grafts.

Read more
New Study Reconfirms COMS® Effectiveness and Gives Insights to Potential New Applications for Wound Care
Piomic Medical Announces First Patients Enrolled in MAVERICKS Study Sites

03 Sep 2023

Trial seeks to assure Piomic’s COMS® treatment is safe and effective in therapy-refractory diabetic foot ulcers

Read more
Piomic Medical Announces First Patients Enrolled in MAVERICKS Study Sites
Piomic receives Medicare Category B Designation for MAVERICKS clinical trial

31 Aug 2023

CMS has approved the COMS One device for Category B designation and for Medicare coverage purposes during Piomic's IDE study

Read more
Piomic receives Medicare Category B Designation for MAVERICKS clinical trial
Piomic receives certification under MDR, the new European Medical Device Regulation

27 Apr 2023

Piomic Medical has received certificates according to MDR for its Class IIa and Class Is medical devices of the COMS® One Therapy System.

Read more
Piomic receives certification under MDR, the new European Medical Device Regulation
Bernard Laurel appointed as the President of Piomic Medical Inc.

10 Feb 2023

M&A experienced advanced wound care leader appointed as President of US Subsidiary Piomic Medical Inc.

Read more
Bernard Laurel appointed as the President of Piomic Medical Inc.
Piomic Medical receives unconditional FDA IDE approval for U.S. pivotal trial

01 Dec 2022

Piomic Medical receives unconditional IDE approval from the FDA for MAVERICKS, the pivotal study for the COMS® One Therapy System in patients with refractory diabetic foot ulcers.

Read more
Piomic Medical receives unconditional FDA IDE approval for U.S. pivotal trial

Events calendar

Don't miss our updates!
You must complete your email.
You must accept our Privacy Policy